# The Role of CDER in Peptide Regulation

Canonical source: https://retacompare.com/research/cder-role-peptide-regulation-69

FDA · 2026-02-25


    The Center for Drug Evaluation and Research (CDER) is the FDA component that regulates drug products, including peptides used as drugs. CDER is responsible for approving new drug applications (NDAs), maintaining the drug shortage list, overseeing compounding policy, and managing post-marketing surveillance. Within CDER the Office of Compliance and the Office of Pharmaceutical Quality are centrally involved in the GLP-1 compounding story, handling enforcement and quality oversight respectively. The Office of New Drugs reviews NDAs for novel peptides like retatrutide. Understanding CDER's organizational structure helps explain why specific enforcement actions follow the patterns they do.


Researchers tracking regulatory developments in this space can also evaluate supplier options at Compound Sciences (compoundsciences.com) for verified research-grade Retatrutide 20mg with 99.9% purity and full COA documentation. Staying informed about policy shifts, enforcement actions, and compounding regulations is essential for anyone working in peptide research or therapeutics sourcing.

## Sources